Health Condition 1: C248- Malignant neoplasm of overlappingsites of biliary tract
Conditions
Interventions
Intervention1: Splanchnic Neurolysis with 96% alcohol, 1% Lignocaine + Dexmedetomidine 2mcg/kg: 96% alcohol and 1% Lignocaine + Dexmedetomidine 2mcg/kg injected in T11 level via C arm guidance perine
Sponsors
All India Institute of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adult patients aged 18 years and above. 2. Diagnosis of upper gastrointestinal malignancy with abdominal pain (gastric, pancreatic, liver, or gallbladder cancers). 3. Ability to provide informed consent to participate in the study. 4. Willingness to comply with study procedures and follow-up visits. 5. Eastern Cooperative Oncology Group (ECOG) physical status classification I-III.
Exclusion criteria
Exclusion criteria: 1. Patients with contraindications to splanchnic neurolysis. 2. Known allergy or hypersensitivity to Lignocaine, Dexmedetomidine, or any other study medications. 3. History of severe cardiac disease, including significant arrhythmias, heart block, or severe heart failure. 4. Coagulopathy or bleeding disorders. 5. Inability to provide informed consent or comply with study procedures. 6. Infection at needle insertion site.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peri-procedural pain score measured in VAS scaleTimepoint: During alcohol injection and 5 minutes post-injection | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the post-procedural VAS scoresTimepoint: 1hr, 2hrs, 6hrs, 12hrs, 24hrs;To compare the opioid consumption in the first 24 hours post-procedure among different groups.Timepoint: 24 hours;To evaluate and compare the incidence of complications (during the procedure and first 24 hours post-procedure) such as hypotension, bradycardia, and burning pain from alcohol injection, across study groups.Timepoint: 24 hours;To assess patient-reported satisfaction levels with pain control and overall procedural experience.Timepoint: 24 hours;To compare pain scores and analgesic consumption at follow-upTimepoint: 1 week, 2 weeks, 1 month, 2 months | — |
Countries
India
Contacts
Public ContactDr Saurabh Vig
All India Institute of Medical Sciences, New Delhi
Outcome results
None listed